Ottimo Pharma

IgE antibodies
#Antibodies #Bifunctional medicine #Cancer research #Funding #Investment #Ottimo Pharma

Bifunctional medicines to extend the lives of cancer patients

Ottimo Pharma has completed a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets. The round was led… Read More

#Business & Investment #Cancer Research #Editor's Choice #News